Welcome to our dedicated page for CASTLE BIOSCIENCES SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CASTLE BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CASTLE BIOSCIENCES's regulatory disclosures and financial reporting.
Olson Tiffany reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Tiffany Olson received a grant of 11,766 Restricted Stock Units as equity compensation. Each RSU represents the right to receive one share of Castle Biosciences common stock at no purchase price.
The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the company’s next Annual Meeting of Stockholders following the grant date. After this award, Olson holds 11,766 RSUs directly, and the filing shows no additional option or derivative positions.
Goldberg Ellen reported acquisition or exercise transactions in this Form 4 filing.
CASTLE BIOSCIENCES INC director Ellen Goldberg received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents one share of the company’s common stock, so this award covers 11,766 shares. Following the grant, she holds 11,766 RSUs directly.
The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. This is a compensation-related equity award, not an open‑market share purchase or sale.
Harrison Miles reported acquisition or exercise transactions in this Form 4 filing.
CASTLE BIOSCIENCES INC director Miles Harrison received a grant of Restricted Stock Units. On May 28, 2026, he was awarded 11,766 RSUs, each representing the right to receive one share of the company’s common stock. These RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. Following this award, his reported derivative holdings from this grant total 11,766 RSUs held directly.
Cotton Rodney reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Rodney Cotton received a grant of 11,766 Restricted Stock Units. Each RSU represents the right to receive one share of Castle Biosciences common stock. The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next annual meeting of stockholders following the grant date.
Caple Kim reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Kim Caple received a grant of 11,766 Restricted Stock Units (RSUs) linked to the company’s common stock. Each RSU represents one share of common stock, for a total underlying amount of 11,766 shares. The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. After this grant, Caple’s reported derivative holdings from this award total 11,766 RSUs.
BRADBURY DANIEL reported acquisition or exercise transactions in this Form 4 filing.
CASTLE BIOSCIENCES INC director Daniel Bradbury received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of Castle Biosciences common stock. The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders after the grant date. Following this award, Bradbury is reported as holding 11,766 RSUs directly.
Cole G Bradley reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Cole G. Bradley received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of the company’s common stock, giving him 11,766 shares underlying this award after the transaction.
The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027 or the day immediately before the next Annual Meeting of Stockholders following the grant date. This is a compensation-related equity award rather than an open-market stock purchase or sale.
Castle Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected three Class I directors — Ellen Goldberg, Miles D. Harrison and Tiffany P. Olson — each to serve until the 2029 annual meeting, with support ranging from 14.4 million to 15.6 million votes in favor and 2.4 million broker non-votes. They also ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 24.5 million votes for and minimal opposition. In advisory and related votes, stockholders approved the compensation of the company’s named executive officers, with about 21.3 million votes in favor versus 1.3 million against, and approved the non-employee director compensation policy by similar margins.
Castle Biosciences Inc. director Cole G. Bradley reported a compensation-related stock transaction. Bradley exercised previously granted Restricted Stock Units (RSUs), receiving 13,667 shares of Common Stock at a stated price of $0.00 per share. Following this exercise, Bradley directly holds 32,976 shares of Common Stock. Each RSU represents the right to receive one share of Common Stock, with vesting tied to the earlier of a one-year anniversary of the grant date or the day before the next Annual Meeting of Stockholders.
Castle Biosciences director Daniel Bradbury reported routine equity compensation activity. He exercised 13,667 Restricted Stock Units, receiving the same number of shares of Common Stock at a stated price of $0.00 per share.
Following the transactions, he now holds 22,340 shares of Common Stock directly and 13,291 shares indirectly through the Bradbury Family Trust, where he and Annette Bradbury serve as trustees and beneficiaries.